[go: up one dir, main page]

PE20021097A1 - Inmunoconjugados de anticuerpos cd44 citotoxicos - Google Patents

Inmunoconjugados de anticuerpos cd44 citotoxicos

Info

Publication number
PE20021097A1
PE20021097A1 PE2002000420A PE2002000420A PE20021097A1 PE 20021097 A1 PE20021097 A1 PE 20021097A1 PE 2002000420 A PE2002000420 A PE 2002000420A PE 2002000420 A PE2002000420 A PE 2002000420A PE 20021097 A1 PE20021097 A1 PE 20021097A1
Authority
PE
Peru
Prior art keywords
compound
specific
antibody
vff
formula
Prior art date
Application number
PE2002000420A
Other languages
English (en)
Inventor
Gunther Adolf
Marlies Sproll
Erik Patzelt
Karl-Heinz Heider
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20021097A1 publication Critical patent/PE20021097A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA A(LB)n DONDE A ES UN ANTICUERPO ESPECIFICO PARA CD44, L ES UN RESTO ENLAZADOR, B ES UN COMPUESTO QUE ES TOXICO PARA LAS CELULAS COMO UN MAITANSINOIDE DE FORMULA I DONDE R1 ES H, SR4 DONDE R4 ES METILO, ETILO, ALQUILO; R2 EL Cl, H; R3 ES O, CH3; m ES 1-3 DE PREFERENCIA N2'-DESACETIL-N2'-(3-MERCAPTO-1-OXOPROPIL)MAITANSINA Y n ES 1-10. EL COMPUESTO DONDE DICHO RESTO ENLAZADOR TIENE UN ENLACE QUIMICO DISULFURO CAPAZ DE SER ROTO EN EL INTERIOR DE LA CELULA. LA MOLECULA DE ANTICUERPO ES ESPECIFICA PARA EL EXON v6 DE CD44 HUMANO O ESPECIFICA PARA UN EPITOPO DENTRO DE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO :3. LA MOLECULA DE ANTICUERPO ES MONOCLONAL VFF-18 (DSM ACC2174) O UN ANTICUERPO RECOMBINANTE QUE TIENE LAS REGIONES DETRMINANTES DE LA COMPLEMENTARIDAD (CDR) DE VFF-18.
PE2002000420A 2001-05-18 2002-05-17 Inmunoconjugados de anticuerpos cd44 citotoxicos PE20021097A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01112227A EP1258255A1 (en) 2001-05-18 2001-05-18 Conjugates of an antibody to CD44 and a maytansinoid

Publications (1)

Publication Number Publication Date
PE20021097A1 true PE20021097A1 (es) 2003-02-13

Family

ID=8177473

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000420A PE20021097A1 (es) 2001-05-18 2002-05-17 Inmunoconjugados de anticuerpos cd44 citotoxicos

Country Status (24)

Country Link
EP (2) EP1258255A1 (es)
JP (1) JP2004529963A (es)
KR (1) KR20030097883A (es)
CN (1) CN1509187A (es)
AR (1) AR035977A1 (es)
BG (1) BG108366A (es)
BR (1) BR0209862A (es)
CA (1) CA2443438A1 (es)
CO (1) CO5550468A2 (es)
CZ (1) CZ20033477A3 (es)
EA (1) EA200301159A1 (es)
EE (1) EE200300568A (es)
HR (1) HRP20030932A2 (es)
HU (1) HUP0400046A3 (es)
IL (1) IL157965A0 (es)
MX (1) MXPA03010432A (es)
NO (1) NO20035108L (es)
NZ (1) NZ530167A (es)
PE (1) PE20021097A1 (es)
PL (1) PL365480A1 (es)
SK (1) SK15582003A3 (es)
WO (1) WO2002094325A2 (es)
YU (1) YU91503A (es)
ZA (1) ZA200307364B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
DE10256083A1 (de) * 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
NZ542695A (en) * 2003-05-20 2009-04-30 Immunogen Inc Improved cytotoxic agents comprising new maytansinoids
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
ES2360403T3 (es) * 2003-07-21 2011-06-03 Immunogen, Inc. Conjugado citotóxico específico para el antígeno ca6 y métodos para usar el mismo.
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
ES2539126T3 (es) * 2004-12-09 2015-06-26 Janssen Biotech, Inc. Inmunoconjugados anti integrina, métodos para su producción y su uso
CA2597407C (en) * 2005-02-11 2013-09-10 Immunogen, Inc. Process for preparing stable drug conjugates
JP4949373B2 (ja) 2005-03-10 2012-06-06 モルフォテック、インク． 抗メソテリン抗体
ZA200708694B (en) * 2005-04-15 2009-01-28 Immunogen Inc Elimination of heterogeneous or mixed cell population in tumors
EP1879922A2 (en) 2005-04-22 2008-01-23 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP2662096A1 (en) * 2005-08-24 2013-11-13 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
PT2437790T (pt) 2009-06-03 2019-06-04 Immunogen Inc Métodos de conjugação
UY32913A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
CN107537040A (zh) 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
AU2013326881B2 (en) 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
GB201220901D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
GB201220891D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
GB201220889D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating metastasizing cancers
ES2996807T3 (en) 2013-03-15 2025-02-13 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
WO2015031396A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
WO2016150521A1 (en) * 2015-03-26 2016-09-29 Fundación Imdea Nanociencia Functionalised magnetic nanoparticle
BR112017020149A8 (pt) 2015-03-27 2023-05-02 Regeneron Pharma Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
US12098215B2 (en) 2016-06-06 2024-09-24 Northwestern University Fusion protein construct
CN112105643B (zh) * 2018-02-22 2023-09-26 普众发现医药科技(上海)有限公司 治疗性抗体及其应用
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
DE19648209A1 (de) * 1996-11-21 1998-05-28 Boehringer Ingelheim Int Verfahren zur Tumorzelldepletion CD34-positiver Zellen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
HU230586B1 (hu) * 1999-06-25 2017-02-28 Genentech, Inc. Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására
EP2289549A3 (en) * 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer

Also Published As

Publication number Publication date
CO5550468A2 (es) 2005-08-31
AR035977A1 (es) 2004-07-28
EA200301159A1 (ru) 2004-06-24
CN1509187A (zh) 2004-06-30
EP1258255A1 (en) 2002-11-20
BG108366A (bg) 2004-09-30
PL365480A1 (en) 2005-01-10
CA2443438A1 (en) 2002-11-28
EP1395290A2 (en) 2004-03-10
HUP0400046A3 (en) 2006-02-28
HUP0400046A2 (hu) 2004-04-28
BR0209862A (pt) 2004-06-08
WO2002094325A2 (en) 2002-11-28
EE200300568A (et) 2004-04-15
WO2002094325A3 (en) 2003-04-17
SK15582003A3 (sk) 2004-04-06
HRP20030932A2 (en) 2004-04-30
IL157965A0 (en) 2004-03-28
MXPA03010432A (es) 2004-04-02
YU91503A (sh) 2006-05-25
ZA200307364B (en) 2004-04-20
CZ20033477A3 (en) 2004-05-12
NO20035108D0 (no) 2003-11-17
NZ530167A (en) 2005-10-28
NO20035108L (no) 2003-11-17
KR20030097883A (ko) 2003-12-31
JP2004529963A (ja) 2004-09-30

Similar Documents

Publication Publication Date Title
PE20021097A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos
DE60205891D1 (de) Steroide als agonisten für fxr
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
ATE391174T1 (de) Modifizierter tpo-agonisten antikörper
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
CO5040071A1 (es) Derivados de aminas biciclicas, procesos para su prepara- cion, y composiciones insecticidas que los comprenden
DE69821985D1 (de) Ortho-anthranilamide derivate als antikoagulantien
DE60007329D1 (de) N-heterozyklische derivate als nos inhibitoren
DE69813622D1 (de) Verbindungen für massenspektrometrie bestehend aus nukleinsäure-basen und arylether-massmarkern
ATE252097T1 (de) N-heterocyclische derivate als nos inhibitoren
TR199900090A2 (xx) Benzos�lfon t�revleri
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
EA200500899A1 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
DE69602809D1 (de) Transportvehikel für Makromoleküle
ATE476989T1 (de) Humanisierter monoklonaler antikörper gegen von- willebrand faktor
EA200200732A1 (ru) Замещенные производные фенилпиперазина, их получение и применение
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
EA200501341A1 (ru) Противобактериальные индолоноксазолидиноны, промежуточные соединения для их получения и содержащие их фармацевтические композиции
SE9801494D0 (sv) Novel use
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
BR9902084A (pt) Heterociclos.
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
ATE441642T1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
TR199802091T2 (xx) Alfa-17 ikame/ katk�lama maddesi i�ermeyen yeni pregnan t�revleri.
BR0308601A (pt) inibidores de carboxipeptidase b de plasma

Legal Events

Date Code Title Description
FC Refusal